 | |
| Company type | Public |
|---|---|
| |
| ISIN | DK0015998017 |
| Industry | Biotechnology |
| Founded | 1994; 32 years ago (1994) |
| Headquarters | , Denmark[3] |
Key people | |
| Products | Imvanex,Imvamune,Jynneos,Rabipur/RabAvert,Encepur,Vivotif,Vaxchora,Mvabea,Vimkunya |
| Revenue |  7.062 billionkr. (2023) |
| Total assets | 14.373 billionkr. (2023) |
| Total equity | 10.340 billionkr. (2023) |
Number of employees | 1.379 (2023) |
| Website | bavarian-nordic |
| Footnotes / references [5] | |
Bavarian Nordic A/S is a Danishbiotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered inHellerup,Denmark, with manufacturing facilities inKvistgård, Denmark andThörishaus [de] nearBern, Switzerland.[3] The company has research and development facilities inMartinsried,Germany, as well as offices inUSA,Canada, andFrance. The company usesviral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired byprivate equity firmsPermira andNordic Capital for 19 billionkr. (approximately US$3 billion).[6] However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.[7]
MVA-BN is a proprietary technology developed by Bavarian Nordic. It is derived from theModified vaccinia Ankara virus. MVA-BN is characterized by the inability to replicate in human cells,[8] contrary to othervaccinia-based vaccines, which may replicate in humans, thus potentially causing severe and life-threatening side effects. Developed as the non-replicatingsmallpox andmpox vaccine, MVA-BN is approved inCanada asImvamune,[9] in theEuropean Union, asImvanex,[10] and the United States asJynneos.[11][12][13] The vaccine was supplied for emergency use to theU.S. Strategic National Stockpile as well as other government stockpiles.[citation needed]
The vaccine is being deployed worldwide to combat the2022 mpox outbreak, leading to concerns over vaccine nationalism and hoarding by countries with pre-existing contracts.[14]
The company has worked for several years with theNIAID[15] on the development of afilovirus vaccine forEbola andMarburghemorrhagic fever diseases. In October 2014, following a successful pre-clinical demonstration of the combination vaccine regimen of its multivalent MVA-BN Filovirus vaccine and Crucell/Janssen's AdVac technology based on adenoviral vectors, Bavarian Nordic joined efforts with Crucell Holland B.V., one of theJanssen Pharmaceuticals companies ofJohnson & Johnson to develop and manufacture this vaccine regimen intended for emergency use to help contain the outbreak in West Africa.[16][17][18] In January 2015, the company had produced the first 400,000 doses of the vaccine and the first clinical trial of the vaccine regimen was initiated in the UK, with additional trials planned in the US and Africa.[19] It was approved for medical use in the European Union in July 2020.[20]
In October 2019, it was announced that Bavarian Nordic would acquire travel vaccines Rabipur(/Rabavert) forrabies and Encepur fortick-borne encephalitis (TBE) fromGlaxoSmithKline (GSK).[21][22] In February 2023, it was announced that Bavarian Nordic would acquire travel vaccinesVivotif fortyphoid fever and Vaxchora forcholera, in addition to a late-stage candidate forchikungunya, fromEmergent BioSolutions.[23]
Bavarian Nordic's marketed products and pipeline, as of June 2025.[24][25]
| Product | Indication | Phase | Remark |
|---|---|---|---|
| Imvanex,Imvamune,Jynneos | Smallpox,mpox and disease caused byvaccinia virus | Approved EU 2013-07 Approved Canada 2013-11 Approved US 2019-09-24 | |
| Rabipur/RabAvert | (Pre-/post-exposure protection against)rabies | Approved | |
| Encepur | European (Western)tick-borne encephalitis (TBE) virus | Approved | |
| Mvabea | Ebola andMarburg virus | Approved EU 2020-07-01 | Licensed to Janssen. One dose of Janssen's primerZabdeno (Ad26.ZEBOV) followed 8 weeks later by a dose of Bavarian Nordic's boosterMvabea® (MVA-BN Filo) collectively constitutes Janssen's Ebola vaccine regimen. |
| Vimkunya | Chikungunya | Approved US 2025-02-14 Approved EU 2025-02-28 | |
| MVA-BN WEV | Equine encephalitis virus | II | A Phase 2 clinical study is ongoing.[26] |
Bavarian Nordic is a member of the Medical Countermeasures Coalition, a group of companies, academic institutions, and other organizations dedicated to building an effective medical countermeasure enterprise through sound public policy and strong public-private partnerships.[27]
The company is a funding partner of theBipartisan Commission on Biodefense,[28] and a former donor to theBipartisan Policy Center.[29]
{{cite web}}: CS1 maint: bot: original URL status unknown (link)
This article incorporates text from this source, which is in thepublic domain.
